Advertisement
Screener

ZAI LAB LIMITED (ZLAB) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

ZAI LAB LIMITED Operating Cash Flow

ZAI LAB LIMITED (ZLAB) reported Operating Cash Flow of -$75.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06

  • ZAI LAB LIMITED net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$63.41M.
  • ZAI LAB LIMITED net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$11.91M.
  • ZAI LAB LIMITED net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$26.02M.
  • ZAI LAB LIMITED net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$32.04M.
  • ZAI LAB LIMITED net cash provided by (used in) operating activities for fiscal 2025 was -$150.79M.
  • ZAI LAB LIMITED net cash provided by (used in) operating activities for fiscal 2024 was -$214.87M.
  • ZAI LAB LIMITED net cash provided by (used in) operating activities for fiscal 2023 was -$198.18M.
  • ZAI LAB LIMITED net cash provided by (used in) operating activities for fiscal 2022 was -$367.64M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$63.41M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$75.32M
10-Q · filed 2026-08-06
-$101.34M
derived: sum of 3 quarters · filed 2026-08-06
-$133.38M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$11.91M
10-Q · filed 2026-05-07
-$37.93M
derived: sum of 2 quarters · filed 2026-05-07
-$69.98M
derived: sum of 3 quarters · filed 2026-05-07
-$101.00M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$26.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$58.07M
derived: sum of 2 quarters · filed 2026-02-26
-$89.09M
derived: sum of 3 quarters · filed 2026-08-06
-$150.79M
10-K · filed 2026-02-26
2025-09-30-$32.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$63.07M
derived: sum of 2 quarters · filed 2026-08-06
-$124.77M
10-Q · filed 2025-11-06
-$180.54M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$31.02M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$92.72M
10-Q · filed 2026-08-06
-$148.49M
derived: sum of 3 quarters · filed 2026-08-06
-$175.31M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$61.70M
10-Q · filed 2026-05-07
-$117.47M
derived: sum of 2 quarters · filed 2026-05-07
-$144.29M
derived: sum of 3 quarters · filed 2026-05-07
-$186.46M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$55.77M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$82.59M
derived: sum of 2 quarters · filed 2026-02-26
-$124.76M
derived: sum of 3 quarters · filed 2026-02-26
-$214.87M
10-K · filed 2026-02-26
2024-09-30-$26.82M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$68.99M
derived: sum of 2 quarters · filed 2025-11-06
-$159.10M
10-Q · filed 2025-11-06
-$174.02M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30-$42.17M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$132.28M
10-Q · filed 2025-08-07
-$147.20M
derived: sum of 3 quarters · filed 2026-02-26
-$202.47M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31-$90.11M
10-Q · filed 2025-05-08
-$105.02M
derived: sum of 2 quarters · filed 2026-02-26
-$160.29M
derived: sum of 3 quarters · filed 2026-02-26
-$219.00M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31-$14.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$70.19M
derived: sum of 2 quarters · filed 2026-02-26
-$128.89M
derived: sum of 3 quarters · filed 2026-02-26
-$198.18M
10-K · filed 2026-02-26
2023-09-30-$55.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
-$113.97M
derived: sum of 2 quarters · filed 2024-11-12
-$183.26M
10-Q · filed 2024-11-12
-$292.55M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30-$58.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
-$127.99M
10-Q · filed 2024-08-06
-$237.28M
derived: sum of 3 quarters · filed 2025-02-27
-$363.60M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31-$69.29M
10-Q · filed 2024-05-08
-$178.58M
derived: sum of 2 quarters · filed 2025-02-27
-$304.90M
derived: sum of 3 quarters · filed 2025-02-27
-$349.80M
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31-$109.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
-$235.62M
derived: sum of 2 quarters · filed 2025-02-27
-$280.51M
derived: sum of 3 quarters · filed 2025-02-27
-$367.64M
10-K · filed 2025-02-27
2022-09-30-$126.32M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
-$171.22M
derived: sum of 2 quarters · filed 2023-11-07
-$258.35M
10-Q · filed 2023-11-07
-$411.34M
derived: sum of 4 quarters · filed 2024-02-27
2022-06-30-$44.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07
-$132.03M
10-Q · filed 2023-08-07
-$285.02M
derived: sum of 3 quarters · filed 2024-02-27
-$445.91M
derived: sum of 4 quarters · filed 2024-02-27
2022-03-31-$87.13M
10-Q · filed 2023-05-09
-$240.12M
derived: sum of 2 quarters · filed 2024-02-27
-$401.01M
derived: sum of 3 quarters · filed 2024-02-27
-$466.86M
derived: sum of 4 quarters · filed 2024-02-27
2021-12-31-$152.99M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27
-$313.88M
derived: sum of 2 quarters · filed 2024-02-27
-$379.73M
derived: sum of 3 quarters · filed 2024-02-27
-$549.23M
10-K · filed 2024-02-27
2021-09-30-$160.89M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
-$226.74M
derived: sum of 2 quarters · filed 2022-11-09
-$396.24M
10-Q · filed 2022-11-09
-$440.57M
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30-$65.85M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$235.35M
10-Q · filed 2022-08-09
-$279.68M
derived: sum of 3 quarters · filed 2023-03-01
-$359.08M
derived: sum of 4 quarters · filed 2023-03-01
2021-03-31-$169.50M
10-Q · filed 2022-05-10
-$213.84M
derived: sum of 2 quarters · filed 2023-03-01
-$293.24M
derived: sum of 3 quarters · filed 2023-03-01
-$345.71M
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31-$44.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
-$123.74M
derived: sum of 2 quarters · filed 2023-03-01
-$176.21M
derived: sum of 3 quarters · filed 2023-03-01
-$216.06M
10-K · filed 2023-03-01
2020-09-30-$79.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
-$131.88M
derived: sum of 2 quarters · filed 2021-11-09
-$171.72M
10-Q · filed 2021-11-09
-$211.74M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30-$52.48M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
-$92.32M
10-Q · filed 2021-08-09
-$132.34M
derived: sum of 3 quarters · filed 2022-03-01
-$200.15M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31-$39.84M
10-Q · filed 2021-05-10
-$79.86M
derived: sum of 2 quarters · filed 2022-03-01
-$147.67M
derived: sum of 3 quarters · filed 2022-03-01
2019-12-31-$40.02M
derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01
-$107.83M
derived: sum of 2 quarters · filed 2022-03-01
-$191.01M
10-K · filed 2022-03-01
2019-09-30-$67.81M
derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21
-$150.99M
6-K · filed 2020-01-21
2019-06-30-$83.18M
6-K · filed 2020-09-11
2018-12-31-$44.63M
derived: 10-K 12 month − 6-K 9 month · filed 2021-03-01
-$97.54M
10-K · filed 2021-03-01
-$97.54M
20-F · filed 2019-03-29
2018-09-30-$52.91M
6-K · filed 2020-01-21
2017-12-31-$32.37M
20-F · filed 2020-04-29
-$32.37M
20-F · filed 2019-03-29
2016-12-31-$32.16M
20-F · filed 2019-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
OCULAR THERAPEUTIX, INC (OCUL)United States$2.159B-7.15
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Braveheart Bio, Inc. (BRVE)United States$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67